12:00 AM
 | 
Oct 14, 1996
 |  BC Week In Review  |  Company News  |  Deals

Biorelease deal

BREL announced plans to spin off its blood substitute and drug delivery assets, after which it will engage in a new business of acquiring companies and technology under a new...

Read the full 126 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >